home

pipeline

the team

news

contact

Established in 2016, BiVictriX Therapeutics Ltd is a North West based Biotech focused on developing novel, highly-selective, bispecific ADCs to target unmet need in blood cancer.

Through the company’s novel “Dual Targeting Approach”, BiVictriX aims to challenge the conventional ADC therapeutic approach by providing a step change in target selectivity.

pipeline

the team

Tiffany Thorn BSc. MSc. – Chief Executive Officer

Tiffany Thorn, inventor of the company’s ‘Dual Targeting Approach’, will lead BiVictriX’s operations as CEO.

A co-founder of BiVictriX Therapeutics, Tiffany was previously Marketing and Licensing Manager at ADC Biotechnology Ltd., gaining vital experience of the ADC market and key trends in the sector, before establishing BiVictriX in August 2016.

As a HCPC registered Clinical Immunologist, Tiffany has experience of diagnosing and treating haematological malignancy within a clinical setting and spent several years carrying out this role in the NHS. During this time, Tiffany was awarded the Chief Scientific Officer’s ‘Rising Star Award’ in 2014 for recognition of her work in establishing a regional network to support NHS: Industry collaboration, which was spun out nationally. Tiffany also previously held several technical positions at RedX Pharma Plc, a drug development company focused on the Redox Switch™ technology platform.

Tiffany graduated from Lancaster University with a first class BSc Hons. In Biochemistry with Biomedicine and later gained a MSc Distinction in Clinical Immunology at the University of Manchester.

Dr. Peter Jackson – Non-Executive Chairman

Dr Jackson is a serial life sciences entrepreneur based in the North West of England and has been appointed as Chairman of BiVictriX, responsible for managing shareholder and investor relations.

With > 20 years experience in senior commercial roles, he is also the co-founder of Redx Pharma PLC, RedAg Crop Protection Ltd,  ADC Biotechnology Ltd, YProTech Ltd and Reaxa Ltd and has leveraged over £50m of private investment and grant support into this sector

Pete has over twenty years’ experience in commercialisation of technology in the bio-pharma/fine chemicals sector, and over ten years’ experience in the spin-out and start-up of bio-pharma SMEs.

Formerly Vice President of Avecia's Pharmaceutical Products business unit (2002), he previously held a series of sales and business management roles in the UK, Europe and Japan with ICI and Zeneca.

A graduate of the Universities of East Anglia, UK and Massachusetts USA, Dr. Jackson gained his PhD at Durham University, UK before joining ICI Fine Chemicals in 1989.

David Youngman – Non-Executive Director

David has almost 35 years’ experience in stockbroking and corporate finance and will bring corporate finance advise and strong governance practices to BiVictriX in his role as non-executive Director.

David currently holds the position of Corporate Finance Director at Acceleris Capital Ltd., part of Seneca Partners, an Investment Management and Corporate Advisory services group which specialises in the SME sector.

From May 1995 to 2009, David was Managing Director and Head of Corporate Finance at WH Ireland. During that period, WH Ireland grew from one office with a turnover of less than £1 million to 12 UK offices and an Australian subsidiary with turnover in excess of £30 million.

David, over the course of the last nine years of his stockbroking career, was responsible for a portfolio of over 60 companies admitted to AIM.

news - click on the title to read the news story

contact

response form

BiVictriX Therapeutics Ltd.

Bio Hub, Alderley Park, Alderley Edge, Cheshire SK10 4TG, UK

+44 (0) 7908 719 566

info@bivictrix.com

Submitting Form...

The server encountered an error.

Form received.